Search Results

Your search for Robert J. Motzer, MD matches 52 pages

Showing 51 - 52

By Matthew Stenger / Monday, February 24, 2014 11:18 AM

No Progression-Free Survival Difference for Dovitinib vs Sorafenib in Third-Line Targeted Treatment of Metastatic Renal Cell Carcinoma

Fibroblast growth factor (FGF) pathway activation may be a mechanism of escape from vascular endothelial growth factor (VEGF)-targeted therapies. In a phase III trial reported in The Lancet Oncology, Motzer et al compared the VEGF and FGF receptor tyrosine kinase inhibitor dovitinib vs sorafenib...

kidney cancer

By Matthew Stenger / Friday, September 13, 2013 1:06 PM

Tivozanib Improves Progression-Free Survival but Not Overall Survival vs Sorafenib in Metastatic Renal Cell Carcinoma

Tivozanib is a selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3. In a phase III trial reported in Journal of Clinical Oncology by Robert J. Motzer, MD, of Memorial Sloan-Kettering Cancer Center (MSKCC) and colleagues, tivozanib was found to...

Jun

Today In Oncology

Search Results

Your search for Robert J. Motzer, MD matches 52 pages

No Progression-Free Survival Difference for Dovitinib vs Sorafenib in Third-Line Targeted Treatment of Metastatic Renal Cell Carcinoma

Tivozanib Improves Progression-Free Survival but Not Overall Survival vs Sorafenib in Metastatic Renal Cell Carcinoma

Early Palliative Care Improves Quality of Life for Patients With Breast Cancer in India

Breast Cancer Palbociclib-Based Regimen Approved for HR-Positive, HER2-Positive Metastatic Disease

Advanced Breast Cancer Novel CDK4/6 Inhibitor Plus an Aromatase Inhibitor

FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination With Pembrolizumab for First-Line Treatment of TNBC

Educational Gaps Found in Cardio-Oncology Training